CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG

CardioSenseSystem Compared to Philips Telemetry System Regarding Efficacy and Safety in the Monitoring of ECG

This is a prospective, controlled, comparative clinical trial of a new ECG monitoring system CardioSenseSystem prior CE marking. The aim of the study is to demonstrate that the CardioSenseSystem's cable-free ECG monitoring system (investigational device) is equivalent or better than traditional and accepted industry standard for cable-based ECG monitoring system (control device). In this study accepted industry standard is Philips Intellivue. In order to investigate this, the study will measure ECG monitoring interruptions, management time and alarm performance. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be using both the investigational device and the control device simultaneous for measuring data loss, management time and alarm function up to 24 hours.

Study Overview

• Status: Unknown
• Conditions: Unstable Angina; Cardiac Arrythmias; Heart Valve Disorders; Disorder of Aorta
• Intervention / Treatment: Device: CardioSenseSystem; Device: Philips Intellivue

Detailed Description

A prospective, controlled and comparative clinical trial before CE marking of a new ECG monitoring system CardioSenseSystem. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be monitored by both the investigational device and the control device for measuring data loss, management time and alarm function up to 24 hours. The duration of the study is estimated to 4 months.

CardioSenseSystem is designed to provide wireless high-quality ECG monitoring. The system developed by Novosense AB consists of three components: the CardioPatch, the Novosense Base Station and the Back-End System. The CardioPatch is a wireless sensor capable to record and transmit ECG data. The CardioPatch send ECG data to the Novosense Base Station, which is the receiving unit. The Back-End System is used for presentation, storage and processing of ECG information. The CardioPatch sensor is applied to the body with an adhesive in the same way as a traditional ECG electrode. In contrast, the CardioPatch is a fully integrated unit containing electrodes, ECG amplifier and a radio transmitter. Novosense's wireless ECG sensors, CardioPatch, transmits the ECG signal 24 hours to the Novosense Base Station receiver.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jonas Tilly; Phone Number: +46709905725; Email: jonas.tilly@novosense.se

Study Locations

• Sweden
  • Entrégatan 7
    • Lund, Entrégatan 7, Sweden, SE-222 41
      • VO Thorax o Kärl, Region Skåne
      • Contact: Rikard Linnér, MD PhD EDIC; Phone Number: +4646177376; Email: rikard.linner@skane.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female at least 18 years old.
2. Patient hospitalized at the investigational site and in need of ECG monitoring.
3. Patient with expected alarms during the 24 hours ECG monitoring.
4. Patient who has been informed of the clinical trials purpose, limitations and relevance, and who has voluntarily agreed to participation in the clinical trial by signing the informed consent form.

Exclusion Criteria:

1. Patient with burns.
2. Patient with known allergy or sensitivity to any of the compositions in CardioPatch.
3. Patient with infection in the area where the electrodes are to be placed.
4. Patient with fragile skin (eg after prolonged cortisone treatment).
5. Patient with open sternum / sternum (eg severe heart failure postoperatively) or treatment for infection of the sternum.
6. Patient with mechanical auxiliary heart or ECMO.
7. Patient with implantable defibrillator.
8. Severely ill patient during end of life.
9. Patient participating in any other clinical trial.
10. Patient where the investigator judge that participation may be risky for the patient or obstruct or interfere the implementation of the trial as approved.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ECG monitoring system CardioSenseSystem group	Device: CardioSenseSystem; CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
Active Comparator: ECG monitoring system Philips Intellivue	Device: Philips Intellivue; Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lost of monitoring data	Compare time of interruptions in the monitoring system between the investigational device and the control device.	During 24 hour per subject

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Management time	Compare management time between the investigational device and the control device. This is done by measuring the time required for the sterilization of cables, battery replacements, application of electrodes and cables, and extra management time for applying electrodes and cables if unconnected.	During 24 hour per subject
Number of correct yellow and red alarm	Compare the number of correct yellow and red alarm between the investigational device and the control device.	During 24 hour per subject
Number of false yellow and red alarm	Compare the number of false yellow and red alarm for the investigational device and the control device.	During 24 hour per subject
Incidence and severity of Averse Events	The incidence and severity of adverse events associated with the investigational device and the control device.	During 24 hour per subject

Collaborators and Investigators

• Sponsor: Novosense AB
• Investigators: Principal Investigator: Rikard Linnér, MD PhD EDIC, Skåne University Hospital

Publications and helpful links

Helpful Links

• Sponsors website

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2020
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 30, 2020

Study Registration Dates

• First Submitted: July 23, 2018
• First Submitted That Met QC Criteria: July 31, 2018
• First Posted (Actual): August 1, 2018

Study Record Updates

• Last Update Posted (Actual): September 11, 2020
• Last Update Submitted That Met QC Criteria: September 9, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: Clinical trial; Controlled; Comparative; ECG Monitoring
• Additional Relevant MeSH Terms: Pathologic Processes; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Pain; Neurologic Manifestations; Chest Pain; Angina Pectoris; Disease; Arrhythmias, Cardiac; Heart Valve Diseases; Angina, Unstable
• Other Study ID Numbers: NovoECG; 2018/9 (Registry Identifier: Regional Ethical Review Board in Lund, Sweden); 5.1-2018-18343 (Registry Identifier: Swedish Medical Products Agency)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No